As an SGLT2 inhibitor, the glucose-lowering effect of dapagliflozin does not increase the risk of hypoglycemia (Bailey et al., 2010; Kaku et al., 2014) and is independent of insulin secretion or action (Musso et al., 2012). This evidence concerns the gene INS and Hypoglycemia.